NCT01934335View on ClinicalTrials.gov

Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 21, 2018

Study Completion Date

December 21, 2018

Conditions

Invasive Breast Cancer

Interventions

DRUG

Vandetanib

OTHER

Placebo

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Ronald Weigel

OTHER